YABAO PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.56 CNY | +1.23% |
|
+6.67% | -4.93% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,399 | 4,489 | 3,835 | 6,992 | 4,528 | 5,215 |
| Enterprise Value (EV) 1 | 4,634 | 4,924 | 4,132 | 7,053 | 4,301 | 4,807 |
| P/E ratio | 16.2 x | 326 x | 35.7 x | 37.4 x | 43.3 x | 26.4 x |
| Yield | 4.44% | 0.34% | 1% | 0.88% | 0.85% | - |
| Capitalization / Revenue | 1.51 x | 1.48 x | 1.47 x | 2.53 x | 1.67 x | 1.79 x |
| EV / Revenue | 1.59 x | 1.62 x | 1.59 x | 2.55 x | 1.58 x | 1.65 x |
| EV / EBITDA | 9.01 x | 9.52 x | 14.4 x | 19.2 x | 12.7 x | 9.99 x |
| EV / FCF | 13.7 x | 80.9 x | 15.7 x | 25.5 x | 12.5 x | 12.4 x |
| FCF Yield | 7.29% | 1.24% | 6.36% | 3.92% | 8% | 8.06% |
| Price to Book | 1.5 x | 1.67 x | 1.38 x | 2.39 x | 1.52 x | 1.75 x |
| Nbr of stocks (in thousands) | 781,390 | 770,000 | 770,000 | 770,000 | 770,000 | 755,851 |
| Reference price 2 | 5.630 | 5.830 | 4.980 | 9.080 | 5.880 | 6.900 |
| Announcement Date | 4/23/19 | 4/24/20 | 4/23/21 | 4/27/22 | 4/25/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2,918 | 3,042 | 2,602 | 2,764 | 2,718 | 2,910 |
| EBITDA 1 | 514.5 | 517.2 | 286.1 | 366.8 | 337.4 | 481.1 |
| EBIT 1 | 344.2 | 346 | 117.4 | 196.7 | 178.1 | 325.5 |
| Operating Margin | 11.79% | 11.37% | 4.51% | 7.11% | 6.55% | 11.19% |
| Earnings before Tax (EBT) 1 | 330 | 49.88 | 127.4 | 201.6 | 125.6 | 219 |
| Net income 1 | 273.3 | 13.91 | 107.4 | 187.1 | 104.7 | 199.6 |
| Net margin | 9.37% | 0.46% | 4.13% | 6.77% | 3.85% | 6.86% |
| EPS 2 | 0.3483 | 0.0179 | 0.1394 | 0.2430 | 0.1359 | 0.2615 |
| Free Cash Flow 1 | 337.9 | 60.85 | 262.6 | 276.4 | 343.9 | 387.4 |
| FCF margin | 11.58% | 2% | 10.09% | 10% | 12.65% | 13.31% |
| FCF Conversion (EBITDA) | 65.66% | 11.76% | 91.8% | 75.35% | 101.91% | 80.53% |
| FCF Conversion (Net income) | 123.6% | 437.55% | 244.61% | 147.74% | 328.58% | 194.1% |
| Dividend per Share 2 | 0.2500 | 0.0200 | 0.0500 | 0.0800 | 0.0500 | - |
| Announcement Date | 4/23/19 | 4/24/20 | 4/23/21 | 4/27/22 | 4/25/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 234 | 435 | 297 | 61.7 | - | - |
| Net Cash position 1 | - | - | - | - | 227 | 409 |
| Leverage (Debt/EBITDA) | 0.4555 x | 0.8409 x | 1.04 x | 0.1682 x | - | - |
| Free Cash Flow 1 | 338 | 60.8 | 263 | 276 | 344 | 387 |
| ROE (net income / shareholders' equity) | 9.58% | 0.38% | 3.93% | 6.36% | 3.5% | 6% |
| ROA (Net income/ Total Assets) | 4.68% | 4.73% | 1.76% | 3.04% | 2.71% | 5.1% |
| Assets 1 | 5,842 | 293.9 | 6,092 | 6,158 | 3,859 | 3,917 |
| Book Value Per Share 2 | 3.760 | 3.490 | 3.610 | 3.800 | 3.860 | 3.940 |
| Cash Flow per Share 2 | 1.020 | 0.6300 | 0.4600 | 0.6200 | 0.8700 | 0.8200 |
| Capex 1 | 68 | 157 | 62.9 | 95.1 | 62.2 | 99.9 |
| Capex / Sales | 2.33% | 5.16% | 2.42% | 3.44% | 2.29% | 3.43% |
| Announcement Date | 4/23/19 | 4/24/20 | 4/23/21 | 4/27/22 | 4/25/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.93% | 640M | |
| +20.61% | 43.18B | |
| +20.67% | 22.59B | |
| +15.34% | 14.56B | |
| +43.35% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- 600351 Stock
- Financials Yabao Pharmaceutical Group Co., Ltd
